Characteristics of discordance between amyloid positron emission tomography and plasma amyloid-β 42/40 positivity-Reference-Cited by-同舟云学术

Characteristics of discordance between amyloid positron emission tomography and plasma amyloid-β 42/40 positivity

Published:2024-02-10 Issue:1 Volume:14 Page:
ISSN:2158-3188
Container-title:Translational Psychiatry
language:en
Short-container-title:Transl Psychiatry

Author:

Pyun Jung-Min^ORCID,Park Young Ho,Youn Young Chul,Kang Min Ju,Shim Kyu Hwan,Jang Jae-Won^ORCID,You Jihwan,Nho Kwangsik,Kim SangYun^ORCID, ,Weiner Michael W.,Aisen Paul,Petersen Ronald,Jack Clifford R.,Jagust William,Trojanowki John Q.,Toga Arthur W.,Beckett Laurel,Green Robert C.,Saykin Andrew J.,Morris John,Shaw Leslie M.,Sorensen Greg,Carrillo Maria,Kuller Lew,Raichle Marc,Paul Steven,Davies Peter,Fillit Howard,Hefti Franz,Holtzman David,Mesulam M. Marcel,Potter William,Snyder Peter,Hendrix James,Vasanthakumar Aparna,Montine Tom,Rafii Michael,Chow Tiffany,Raman Rema,Jimenez Gustavo,Donohue Michael,Gessert Devon,Harless Kelly,Salazar Jennifer,Cabrera Yuliana,Walter Sarah,Hergesheimer Lindsey,Harvey Danielle,Donohue Michael,Bernstein Matthew,Fox Nick,Thompson Paul,Schuff Norbert,DeCArli Charles,Borowski Bret,Gunter Jeff,Senjem Matt,Vemuri Prashanthi,Jones David,Kantarci Kejal,Ward Chad,Koeppe Robert A.,Foster Norm,Reiman Eric M.,Chen Kewei,Mathis Chet,Landau Susan,Cairns Nigel J.,Franklin Erin,Lee Virginia,Korecka Magdalena,Figurski Michal,Crawford Karen,Neu Scott,Foroud Tatiana M.,Potkin Steven,Shen Li,Faber Kelley,Kim Sungeun,Albert Marilyn,Frank Richard,Hsiao John,Khachaturian Zaven

Abstract

AbstractVarious plasma biomarkers for amyloid-β (Aβ) have shown high predictability of amyloid PET positivity. However, the characteristics of discordance between amyloid PET and plasma Aβ42/40 positivity are poorly understood. Thorough interpretation of discordant cases is vital as Aβ plasma biomarker is imminent to integrate into clinical guidelines. We aimed to determine the characteristics of discordant groups between amyloid PET and plasma Aβ42/40 positivity, and inter-assays variability depending on plasma assays. We compared tau burden measured by PET, brain volume assessed by MRI, cross-sectional cognitive function, longitudinal cognitive decline and polygenic risk score (PRS) between PET/plasma groups (PET−/plasma−, PET−/plasma+, PET+/plasma−, PET+/plasma+) using Alzheimer’s Disease Neuroimaging Initiative database. Additionally, we investigated inter-assays variability between immunoprecipitation followed by mass spectrometry method developed at Washington University (IP-MS-WashU) and Elecsys immunoassay from Roche (IA-Elc). PET+/plasma+ was significantly associated with higher tau burden assessed by PET in entorhinal, Braak III/IV, and Braak V/VI regions, and with decreased volume of hippocampal and precuneus regions compared to PET−/plasma-. PET+/plasma+ showed poor performances in global cognition, memory, executive and daily-life function, and rapid cognitive decline. PET+/plasma+ was related to high PRS. The PET−/plasma+ showed intermediate changes between PET−/plasma− and PET+/plasma+ in terms of tau burden, hippocampal and precuneus volume, cross-sectional and longitudinal cognition, and PRS. PET+/plasma− represented heterogeneous characteristics with most prominent variability depending on plasma assays. Moreover, IP-MS-WashU showed more linear association between amyloid PET standardized uptake value ratio and plasma Aβ42/40 than IA-Elc. IA-Elc showed more plasma Aβ42/40 positivity in the amyloid PET-negative stage than IP-MS-WashU. Characteristics of PET−/plasma+ support plasma biomarkers as early biomarker of amyloidopathy prior to amyloid PET. Various plasma biomarker assays might be applied distinctively to detect different target subjects or disease stages.

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41398-024-02766-6.pdf

Reference22 articles.

1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.

2. Pyun JM, Kang MJ, Ryoo N, Suh J, Youn YC, Park YH, et al. Amyloid metabolism and amyloid-targeting blood-based biomarkers of Alzheimer’s disease. J Alzheimers Dis. 2020;75:685–96.

3. Janelidze S, Teunissen CE, Zetterberg H, Allué JA, Sarasa L, Eichenlaub U, et al. Head-to-head comparison of 8 plasma amyloid-β 42/40 assays in Alzheimer disease. JAMA Neurol. 2021;78:1375–82.

4. Teunissen CE, Verberk IMW, Thijssen EH, Vermunt L, Hansson O, Zetterberg H, et al. Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation. Lancet Neurol. 2022;21:66–77.

5. Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid. Ann Neurol. 2013;74:826–36.